Refeyn, a frontrunner in the development of groundbreaking mass photometry instrumentation, is experiencing a surge in its global deployment within contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs). To underscore this significant expansion, Refeyn has unveiled a new online resource that elucidates how prominent CROs and CDMOs are revolutionizing their process development and manufacturing protocols through the application of mass photometry. This platform also furnishes researchers with an interactive instrument to identify and engage with these forward-thinking organizations.
The swift embrace of mass photometry is a direct consequence of the escalating demand for analytical methodologies that are not only expedient and dependable but also economically viable for the characterization of proteins and mRNA, the development of antibodies, and the analysis of viral vectors. Introduced less than a decade ago, this technology has since been referenced in approximately 1,500 scholarly works and is currently utilized by a substantial 90% of leading biopharmaceutical corporations. Moreover, its utility is further bolstered by GMP-compliant software tailored for AAV analytics and its endorsement by regulatory bodies, including the US Pharmacopeia, China’s NIFDC, and the British Pharmacopeia, attesting to its suitability for deployment across all stages from initial development through manufacturing and quality control.
Leading CROs and CDMOs are leveraging mass photometry to furnish rapid, label-free insights into critical quality parameters. These include the purity ratios of AAV capsids (differentiating between full, empty, and partial particles), the integrity and purity of mRNA, and the characterization of emerging antibody classes. This capability empowers their clientele to make more judicious development decisions at earlier stages, concurrently minimizing sample utilization and reducing workflow durations, thereby addressing analytical complexities that pose significant challenges for conventional techniques.
“The incorporation of mass photometry into our analytical suite significantly curtails the overall expenditure associated with novel therapeutics by streamlining both developmental and manufacturing timelines. Through collaborative efforts with partners globally, we are broadening the accessibility of this technology, enabling organizations to either acquire their own instrumentation or engage with reputable service providers. Ultimately, this endeavor serves to expedite the journey from initial discovery to patient availability.”
Gabriella Kiss, PhD, Director of Market Development, Refeyn
CROs and CDMOs are presented with an opportunity to collaborate with Refeyn, thereby enhancing their analytical offerings and satisfying the escalating requirement for accelerated, high-fidelity data generation. Concurrently, biopharmaceutical entities can access the advanced capabilities of mass photometry through Refeyn’s expanding network of strategic partners.
